Boston – Hunneman announced that it brokered the $11,050,000 purchase of 900 Middlesex Turnpike, Bldg. 2 in Billerica, MA.
Hunneman’s Vice President Ken Oppenheim represented Buyer, ChemGenes Corporation and the Seller was Rhino Capital lead by Managing Principal Michael Olson.
ChemGenes, a biotechnology company out of Wilmington, was in search of a significant amount of infrastructure needed for lab space as well as manufacturing space to serve as their Headquarters for immediate occupancy.
“It was a pleasure to assist ChemGenes on its acquisition of 900 Middlesex Turnpike, acquiring quality R&D/light manufacturing space with growth potential in this market has never been more challenging,” said Oppenheim of Hunneman.
ChemeGenes is a prominent, critical manufacturer of DNA & RNA in the fight against this Pandemic.
“As a world-renowned producer of diagnostic and therapeutic tools, we have persistently been in the forefront to combat many diseases, in particular COVID-19,” said Amar Raj, CFO of ChemGenes. “In order to achieve these goals and meet increased demand, we have had to expedite an extensive relocation process.”
Hunneman’s Oppenheim worked alongside ChemGenes searching the market to fit their immediate needs. 900 Middlesex Turnpike, Bldg. 2 in Billerica served that imminent need, offering 75,000 SF of lab, manufacturing, office and warehouse space.
ChemGenes Corporation is a privately-held, biotechnology company with a current facility located in Wilmington, MA. ChemGenes Corp. began as a supplier of “Ultra Pure Products” and progressed as an active Contract Researcher. The corporation is a partner and expert to researchers engaged in the field of DNA/RNA synthesis.